I. AMENDMENTS

IN THE SPECIFICATION:

At page 1, please delete the existing title and insert therefor the following:--ADENOVIRUS p53 COMPOSITIONS AND METHODS--.

At page 2, please delete lines 3-7 and insert therefor the following: --This is a continuation of co-pending application Serial No. 07/960,513 filed October 13, 1992, which is a CIP of 07/665,538 filed March 6, 1991. The government owns rights in the present invention pursuant to NIH grants RO1 CA 45187 and CA 16672--.

IN THE CLAIMS:

Please cancel claims 1-65 without prejudice or disclaimer.

Please add the following new claims:

--66. An adenovirus vector comprising a wild type p53 gene under the control of a promoter.

67. The vector of claim 66, wherein the promoter is the CMV promoter.

68. The vector of claim 66, wherein the promoter is the β-actin promoter.

69. The vector of claim 66, wherein the promoter is the SV40 promoter.

70. The vector of claim 66, wherein the promoter is the RSV promoter.

71. The vector of claim 66, wherein the wild type p53 gene is a human gene.

72. A method of treating a cancer cell in a patient comprising introducing to the cell an adenovirus vector comprising a wild type p53 gene under the control of a promoter.

73. The method of claim 72, wherein the promoter is the CMV promoter.

74. The method of claim 72, wherein the cancer cell is a lung cancer cell.

75. The method of claim 74, wherein the lung cancer cell is a NSCLC cell.

76. The method of claim 72, wherein the cancer cell is in a tumor.

77. The method of claim 76, wherein the tumor is an endobronchial tumor.

78. The method of claim 76, further comprising resecting the tumor.

79. The method of claim 78, wherein the tumor resection occurs prior to introduction of the vector.

80. The method of claim 79, wherein the vector is directly introduced into the residual tumor site.

81. The method of claim 72, wherein the vector is introduced to the cell by regional delivery to the patient.

82. The method of claim 72, wherein the vector is introduced to the cell by lavage to the patient.

83. A method for treating a cell having a mutant p53 gene comprising introducing to the cell an adenovirus vector comprising a wild type p53 gene under the control of a promoter.